香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 本 公 告 載 有 前 瞻 性 陳 述，當 中 涉 及 風 險 及 不 明 朗 因 素。除 過 往 事 實 的 陳 述 外， 所 有 陳 述 均 屬 前 瞻 性 陳 述。該 等 陳 述 涉 及 已 知 及 未 知 風 險、不 明 朗 因 素 及 其 他 因 素，當 中 部 分 非 本 公 司 所 能 控 制，可 能 導 致 實 際 業 績、表 現 或 成 果 與 前 瞻 性 陳 述 所 明 示 或 暗 示 者 存 在 重 大 差 異。 閣下不應倚賴前瞻性陳述預測未來事 件。我 們 概 不 負 責 更 新 或 修 訂 任 何 前 瞻 性 陳 述，即 使 出 現 新 資 料、未 來 事 件 或 其 他 事 項 亦 然。 Zhaoke Ophthalmology Limited 兆科眼科有限公司 （於英屬處女群島註冊成立並於開曼群島存續的有限公司） （股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於英屬處女群島註冊成立並於開曼群島存續的有限公司） 兆科眼科有限公司 香 港，2026年3月11日 （股份代號：6622） 於 本 公 告 日 期，本 公 司 董 事 會 包 括 執 行 董 事 李 小 羿 博 士 及 戴 向 榮 先 生；非 執 行 董 事 李 燁 妮 女 士 及 張 甜 甜 女 士；以 及 獨 立 非 執 行 董 事 黃 顯 榮 先 生、盧 毓 琳 教 授 及 劉 懷 鏡 先 生。 董事會會議通告 兆 科 眼 科 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於2026年3月25日（星 期 三）舉 行，以（其 中 包 括）考 慮 及 批 准 本 公 司 及 其 附 屬 公 司截至2025年12月31日 止 年 度 的 年 度 業 績 及 其 登 載。 承董事會命 Zha ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年2月28日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 兆科眼科有限公司 | | | 呈交日期: | 2026年3月3日 | | | I. 法定/註冊股本變動 | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06622 | 說明 | 兆科眼科有限公司 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,600,000,000,000 USD | | 0.00000025 | USD | | 400,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,60 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 兆科眼科有限公司 | | | 呈交日期: | 2026年2月3日 | | | I. 法定/註冊股本變動 | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06622 | 說明 | 兆科眼科有限公司 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,600,000,000,000 | USD | 0.00000025 | USD | | 400,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,60 ...

Group 1 - The stock of Zhaoke Ophthalmology-B (06622.HK) has increased by over 5%, currently up 5.28% at HKD 3.79 [1] - The trading volume reached HKD 6.119 million [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5%, currently trading at HKD 3.79, with a transaction volume of HKD 6.119 million, following the announcement of FDA approval for its eye drop product [1] Group 1: FDA Approval and Product Details - Zhaoke Ophthalmology announced that its partner, Tenpoint Therapeutics, has received FDA approval for the commercialization of Carbachol and Bromonidine Tartrate Eye Drops (2.75%/0.1%) [1] - The eye drop, known as BRIMOCHOL PF during clinical trials, will be marketed in the U.S. under the name YUVEZZI, aimed at treating presbyopia [1] Group 2: Commercial Strategy and Partnerships - The FDA approval is considered a strong catalyst for Zhaoke Ophthalmology as it formulates its commercialization strategy [1] - The company has established a partnership network for BRIMOCHOL PF, which currently includes eight commercial partners across the Asia-Pacific region (including South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan/Hong Kong/Macau, Singapore, and Vietnam) and the Middle East [1] - With FDA recognition, Zhaoke anticipates accelerating the market launch of the drug, marking a significant global milestone [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5% following the announcement of FDA approval for its eye drop product, marking a significant milestone for the company [1] Group 1: Company Developments - Zhaoke Ophthalmology announced that its partner, Tenpoint Therapeutics, Ltd., received FDA approval for the commercialization of Carbachol and Bromfenac eye drops (2.75%/0.1%) [1] - The eye drop, known as BRIMOCHOL™ PF during clinical trials, will be marketed in the U.S. under the name YUVEZZI™ for the treatment of presbyopia [1] - The FDA approval is seen as a strong catalyst for Zhaoke's commercialization strategy, with the company having established a partnership network across the Asia-Pacific region and the Middle East [1] Group 2: Market Impact - Following the FDA approval announcement, Zhaoke Ophthalmology's stock rose by 5.28%, reaching HKD 3.79, with a trading volume of HKD 6.119 million [1] - The approval is expected to accelerate the market entry of the drug, representing an important global milestone for the company [1]

Core Insights - The approval of BRIMOCHOL™ PF marks a significant breakthrough in the treatment of presbyopia, introducing the world's first combination eye drop for this condition [2][4][11] - The drug's approval by the FDA highlights its efficacy and safety, addressing a substantial unmet clinical need in the presbyopia treatment market [4][5][11] Drug Approval and Clinical Data - BRIMOCHOL™ PF has been validated through two key Phase III clinical trials, demonstrating superior efficacy compared to its individual active components [4][5] - The first Phase III trial (BRIO-I) confirmed the drug's effectiveness, while the second trial (BRIO-II) showed significant improvements in uncorrected near visual acuity without compromising distance vision [4][5] - The drug has shown good tolerability with no serious treatment-related adverse events reported during over 72,000 treatment days [4][5] Market Potential and Strategic Positioning - Approximately 1.2 billion people globally are affected by presbyopia, with a significant portion of the population over 50 years old impacted [5] - The approval of BRIMOCHOL™ PF fills a market gap for combination therapies in presbyopia, positioning the company favorably against competitors [5][11] - The company is actively pursuing global business development (BD) partnerships, having licensed the drug to eight countries in the Asia-Pacific region and six in the Middle East [2][6][8] Business Development Strategy - The company's BD strategy focuses on leveraging partnerships to expedite market entry in key regions, contrasting with the self-reliant approach of some competitors [6][8] - The FDA's approval is expected to facilitate faster regulatory processes in other countries, potentially simplifying or waiving clinical trial requirements based on FDA data [8][9] - This proactive approach is anticipated to significantly shorten the commercialization timeline compared to the typical 3-5 year approval cycle in the region [9] Financial Outlook and Growth Potential - The approval of BRIMOCHOL™ PF is expected to be a core revenue driver for the company in the coming years, alongside other innovative products in its pipeline [9][11] - The company's stock has shown a recovery, with a more than 150% increase since 2025, reflecting positive market expectations for its growth [11] - The ongoing development of other products, such as cyclosporine eye gel and low-concentration atropine, further supports the company's international expansion and diversification strategy [9][11]

Core Viewpoint - Tenpoint Therapeutics, Ltd. has received FDA approval for the commercialization of BRIMOCHOL PF, an innovative eye drop treatment for presbyopia, which will be marketed as YUVEZZI in the U.S. [1] Group 1 - The approval follows the successful completion of Phase 3 clinical trials, with the first key Phase 3 study (BRIO I) demonstrating the combination therapy's superiority over individual therapies [1] - The second Phase 3 study (BRIO II) achieved all primary endpoints for near vision improvement, showing a statistically significant increase in binocular uncorrected near visual acuity (BUCNVA) by three lines or more, while binocular uncorrected distance visual acuity (BUCDVA) did not decrease by one line or more [1] Group 2 - During the BRIO II study, BRIMOCHOL PF showed good tolerability with no serious treatment-related adverse events reported, and the incidence of eye redness was low [2] - The report rate of eye redness for subjects receiving BRIMOCHOL PF was 2.8%, significantly lower than the 10.7% for those receiving only carbachol [2] Group 3 - This FDA approval serves as a strong catalyst for the company's commercialization strategy, with a partnership network established across the Asia-Pacific region and the Middle East, including eight commercial partners [2] - With FDA recognition, the company anticipates accelerating the market entry of BRIMOCHOL PF, marking an important global milestone [2]

Core Insights - Tenpoint Therapeutics, Ltd. has received FDA approval for the commercialization of BRIMOCHOL™ PF (2.75%/0.1%), an innovative eye drop for the treatment of presbyopia, which will be marketed as YUVEZZI™ in the U.S. [1][2] - The approval follows the successful completion of Phase 3 clinical trials, with the BRIO I study demonstrating the combination therapy's superiority over individual therapies [1] - The BRIO II study showed that BRIMOCHOL™ PF significantly improved binocular uncorrected near visual acuity (BUCNVA) by three lines or more, with no significant decline in binocular uncorrected distance visual acuity (BUCDVA) [1] Clinical Trial Results - In the BRIO II study, BRIMOCHOL™ PF was well-tolerated, with no serious treatment-related adverse events reported during over 72,000 treatment days [2] - The incidence of eye redness (conjunctival hyperemia) as a side effect was low, with a report rate of 2.8% for BRIMOCHOL™ PF compared to 10.7% for those receiving only carbachol [2] Commercial Strategy - The approval serves as a strong catalyst for the company's commercialization strategy, having established a partnership network that includes eight commercial partners across the Asia-Pacific region and the Middle East [2] - With FDA recognition, the company anticipates accelerating the market entry of BRIMOCHOL™ PF, marking a significant global milestone [2]